Recombinant Anti-HER2 Fab Antibody
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
HER2 (human epidermal growth factor receptor 2) is a member of the epidermal growth factor receptor (HER/EGFR/ERBB) family. It is also called ERBB2, CD340 or proto-oncogene Neu. The protein is a receptor tyrosine kinase located on the plasma membrane of cells. Activation of the tyrosine kinase promotes cell proliferation and suppresses apoptosis. HER2 can dimerize with any other member of the ErbB family, which results in auto phosphorylation of tyrosine residues and activation of signal pathways. HER2 is over expressed in a significant proportion of cancer patients, resulting in an increased disease recurrence and poor prognosis. Therefore an early diagnosis of the HER2 status of the tumors is necessary to decide the appropriate treatment. Besides in breast cancer HER2 is over expressed in variety of different tumors. The over expression of HER2 makes it a target for immunotherapy of certain tumor patients. The antibody Trastuzumab (Herceptin) which recognizes HER2 was approved for the treatment of HER2 positive breast cancer patients in 1998. The original approval was for treatment of HER2 positive metastatic breast tumors. Later studies have shown that Herceptin is also beneficial for early stage HER2 positive tumor patients and it is approved as an adjuvant treatment. Additionally the antibody is now approved also for other HER2 positive tumors (metastatic gastric adenocarcinoma). This antibody is made from a humanized Fab fragment making it specific, efficient, and effective. Humanized Recombinant Anti-HER2 Fab fragment Antibody is useful for researchers interested in Cancer research.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.